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Cardiovascular disease remains the main cause of morbidity and mortality in patients 
with diabetes. The risk of vascular ischemia is increased in this population and outcome 
following an event is inferior compared to individuals with normal glucose metabolism. 
The reasons for the adverse vascular profile in diabetes are related to a combination 
of more extensive atherosclerotic disease coupled with an enhanced thrombotic envi-
ronment. Long-term measures to halt the accelerated atherosclerotic process in dia-
betes have only partially addressed vascular pathology, while long-term antithrombotic 
management remains largely similar to individuals without diabetes. We address in this 
review the pathophysiological mechanisms responsible for atherosclerosis with special 
emphasis on diabetes-related pathways. We also cover the enhanced thrombotic milieu, 
characterized by increased platelet activation, raised activity of procoagulant proteins 
together with compromised function of the fibrinolytic system. Potential new therapeu-
tic targets to reduce the risk of atherothrombosis in diabetes are explored, including 
alternative use of existing therapies. Special emphasis is placed on diabetes-specific 
therapeutic targets that have the potential to reduce vascular risk while keeping an 
acceptable clinical side effect profile. It is now generally acknowledged that diabetes is 
not a single clinical entity but a continuum of various stages of the condition with each 
having a different vascular risk. Therefore, we propose that future therapies aiming to 
reduce vascular risk in diabetes require a stratified approach with each group having a 
“stage-specific” vascular management strategy. This “individualized care” in diabetes 
may prove to be essential to improve vascular outcome in this high risk population.
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iNTRODUCTiON
The prevalence of diabetes continues to increase and is reaching epidemic proportions.1 The vast 
majority of these patients have type 2 diabetes characterized early in the disease process by insulin 
resistance (IR) followed by pancreatic β-cell failure leading to elevated blood glucose and emergence 
of diabetes (1–3). A minority have type 1 diabetes, secondary to immune destruction of the β-cells. 
1 http://www.who.int.
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However, these individuals can also develop IR leading to double 
diabetes, which has features of both type 1 and type 2 diabetes (4), 
and this group appears to have an enhanced vascular risk.
Despite advances in therapy, cardiovascular disease (CVD) 
remains the main cause of morbidity and mortality in diabetes 
(5, 6). Similarly to CVD in individuals without diabetes, an 
increased inflammatory response and an enhanced thrombotic 
milieu represent the two main pathological pathways underpin-
ning atherothrombosis in diabetes. However, the adverse vascular 
process is accelerated in diabetes, secondary to a combination of 
IR and elevated blood glucose levels. Understanding the exact 
mechanisms involved in disease initiation and progression is 
crucial in order to develop effective vascular preventative and 
therapeutic treatment strategies (7–9).
This review summarizes the pathophysiological mechanisms 
responsible for increased atherothrombotic risk in diabetes, 
addresses current treatment modalities, and explores additional 
pathways that can be targeted to reduce vascular events in this 
high-risk population.
Pathophysiology
Both extensive vascular pathology and an enhanced thrombotic 
environment contribute to premature vascular occlusive events 
and poor clinical outcome in patients with diabetes.
A normal endothelial cell (EC) function is the key to maintain 
vascular health. EC dysfunction is one of the earliest abnormali-
ties in the atherothrombotic process, which also contributes to 
the latter stages of the disease. Another central mechanism in 
vascular pathology is systemic inflammation, which promotes 
vascular damage. EC dysfunction and an inflammatory milieu 
are both associated with a prothrombotic and hypofibrinolytic 
environment, facilitating vascular occlusion and leading to 
myocardial infarction, stroke, and occlusive peripheral vascular 
disease, common complications in patients with diabetes.
EC Dysfunction
The endothelium plays an important role in maintaining vascular 
homeostasis by regulating vasodilation and vasoconstriction, 
thrombosis and fibrinolysis, platelet activation, platelet and 
leukocyte interaction, and smooth muscle cell function. Under 
physiological conditions, the endothelium modulates vascular 
tone by producing and releasing various vasodilator substances, 
most importantly nitric oxide (NO), and vasoconstrictor sub-
stances including endothelin (10, 11). When EC dysfunction 
occurs, secondary to IR with or without elevated blood glucose 
levels, vascular homeostasis is disturbed and the process of ath-
erosclerosis ensues (11, 12). EC dysfunction results in these cells 
expressing adhesion molecules, thus attracting inflammatory cells. 
Moreover, EC dysfunction disrupts the barrier function of these 
cells causing the movement of low-density lipoprotein cholesterol 
(LDL) from vessel lumen into the wall, where it is oxidized to the 
highly atherogenic ox-LDL. This molecule is then taken up by 
inflammatory cells that moved from the blood stream to the ves-
sel wall secondary to increased permeability of dysfunctional EC. 
The uptake of ox-LDL by macrophages results in the formation 
of foam cells, which aggregate together to form the fatty streak, 
the earliest abnormality in the atherosclerotic process, and which 
can be found as early as childhood. An inflammatory reaction is 
followed by deposition of collagen, gradually transforming the 
healthy vessel wall into a series of atherosclerotic plaques. Once 
the atherosclerotic plaque ruptures, it exposes a prothrombotic 
core resulting in activation of platelets and the protein phase 
of coagulation, culminating in the formation of the obstructive 
vascular clot.
Endothelial cell dysfunction plays a role in all stages of the 
atherosclerotic process from initiation of atherosclerosis to 
precipitation of thrombosis (10, 13), as summarized in Figure 1. 
Therefore, therapy targeted at improving the health of these cells 
would help to reduce the risk of atherothrombosis. In diabetes, 
this includes general measures, such as ensuring good glycemic 
control, reducing IR, and optimizing blood pressure control. 
However, there are additional steps that can be undertaken to 
target specific pathways, which are further detailed below.
Vascular Inflammation and Atherosclerosis in 
Diabetes
We will concentrate on diabetes-specific pathways for vascular 
pathology related to IR and elevated glucose levels.
Reduced NO bioavailability and elevated levels of reactive 
oxygen species (ROS) play fundamental roles in vascular disease 
in diabetes (Figure  1). IR inhibits NO production by decreas-
ing the activity of endothelial NO synthase (eNOS) resulting in 
reduced vasodilation (14–16). In addition to reduced production 
of vasodilators, there is an increased production of vasoconstric-
tors in diabetes. For example, the vasoconstrictor endothelin-1 
is involved with endothelial dysfunction and increased plasma 
levels have been associated with microangiopathy in type 2 dia-
betes (17). Furthermore, increased arterial stiffness in diabetes 
has been associated with phenotype switching of vascular smooth 
muscle cells, a process that appears to be controlled by microR-
NAs (miRNAs); miR-145 has recently been shown to modulate 
the phenotypic switch of vascular smooth muscle cells from a 
contractile to a proliferative state in atherosclerosis (18, 19).
Decreased NO bioavailability has also been related to platelet 
activation. An in vivo study in diabetic mice has demonstrated 
that inhibiting NO synthase reduced platelet vasodilator-stim-
ulated phosphoprotein (VASP) phosphorylation and increased 
fibrinogen-platelet binding and expression of P-selectin as well 
as CD40 ligand. Diabetic mice also exhibited reduced VASP 
phosphorylation, increased fibrinogen-platelet binding, and 
enhanced expression of P-selectin/CD40 ligand, which was 
rescued by endothelial-specific restoration of NO production 
(20). This emphasizes the importance of NO production by ECs 
in controlling platelet activation, a process that is compromised 
in the presence of endothelial dysfunction.
Hyperglycemia in diabetes and elevated levels of free fatty 
acids enhance ROS production, which in turn compromises NO 
synthesis via a number of cellular mechanisms. More specifi-
cally, free fatty acids bind to Toll-like receptor, activating NF-κB, 
which stimulates inflammation by increasing the expression 
of the inflammatory molecules interleukin (IL)-6 and tumor 
necrosis factor (TNF)-α. Moreover, the stimulation of the toll-
like receptor induces the phosphorylation of insulin receptor 
FigURe 1 | The accelerated vascular pathology and enhanced thrombotic environment in diabetes. Endothelial dysfunction plays a key role in all stages of the 
atherosclerotic process. In the early stages of the disease, insulin resistance and increased levels of glucose and free fatty acids enhance the production of reactive 
oxygen species (ROS) and reduce nitric oxide (NO) synthesis via several mechanisms including activation of NF-κB and protein kinase C (PKC) signaling and 
reduction of endothelial NO synthase (eNOS) activity. Endothelial dysfunction contributes to the impairment of vasodilation, expression of adhesion molecules, and 
further vascular inflammation. In the latter stages of the disease, endothelial dysfunction results in increased platelet activation and a prothrombotic/hypofibrinolytic 
environment which facilitates vascular occlusion and atherothrombosis.
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substrate-1 by c-Jun amino-terminal kinase (JNK) and protein 
kinase C (PKC) causing downregulation of the PI3-kinase/Akt 
pathway and the glucose transporter GLUT-4. Suppression of 
the PI3-kinase/Akt pathway leads to reduced eNOS activity and 
decreased NO production. Furthermore, the increased oxidative 
stress and hyperglycemia, stimulate vascular inflammation via 
several cellular mechanisms, including promoting activation of 
PKC and NF-κB signaling. Secretion of cytokines IL-1 and TNF-α 
enhances NF-κB activity and production of adhesion molecules 
by ECs further aggravating the inflammatory process (21, 22).
Figure 2 summarizes the main mechanistic pathways operat-
ing to increase vascular inflammation in diabetes.
Thrombotic Changes in Diabetes
The metabolic changes including IR and hyperglycemia are 
associated with both increased platelet activation and reduced 
response to antiplatelet therapy, which have been extensively 
reviewed elsewhere (23–26). Briefly, there are two main types of 
antiplatelet agents that are currently used for long-term therapy in 
diabetes. The first targets the thromboxane pathway, represented 
by aspirin, whereas the second targets the P2Y12 pathway, and 
this family of drugs currently includes three agents: clopidogrel, 
prasugrel, and ticagrelor. More antiplatelet agents are in develop-
ment that target additional pathways (26).
Following myocardial infarction, dual antiplatelet therapy 
(DAPT) is used employing agents that target the thromboxane 
and P2Y12 pathways. However, inhibitors of the P2Y12 pathway 
seem to vary in efficacy. In the TRITON trial, DAPT with aspirin 
and prasugrel following myocardial infarction was superior to 
aspirin and clopidogrel but at the expense of increased bleeding 
events, failing to overall improve clinical outcome. A sub-analysis 
of diabetes patients, however, has shown reduction in further 
ischemic events without a significant increase in bleeding risk 
(27), making prasugrel particularly useful for patients with dia-
betes. The newer P2Y12 inhibitor ticagrelorhas also shown both 
biochemical and clinical superiority to clopidogrel when used 
in combination with aspirin following myocardial infarction, 
an effect that was observed in both diabetes and non-diabetes 
patients without an increase in bleeding risk (28–31). Moreover, 
the PEGASUS-TIMI 54 trial showed that ticagrelor addition 
to background aspirin therapy in patients with stable coronary 
artery disease caused significant reduction of cardiovascular risk 
compared with the placebo group (32). The previously docu-
mented reduced efficacy of clopidogrel in diabetes does not seem 
to apply to the newer agent ticagrelor, showing the progress made 
at inhibiting P2Y12 pathway in diabetes. In contrast, the inhibi-
tion of the thromboxane pathway by aspirin remains an area 
of debate. Given the short half-life of aspirin and the increased 
platelet turnover in this condition, the use of twice daily aspirin in 
diabetes has been advocated. Indeed, clinical studies have shown 
a significant reduction in platelet reactivity to thromboxane when 
using aspirin twice daily vs once/day (33–36). However, it remains 
unclear whether twice daily aspirin affects clinical outcome and 
studies in this area are lacking.
A relatively recent development is the implication of 
reticulated platelets in atherothrombotic events (37). These 
are immature platelets that show resistance to the action of 
antiplatelet therapy (38, 39). However, the degree of resistance 
appears to differ comparing antiplatelet agents, with ticagrelor 
the least affected (40). Interestingly, a recent study has shown 
that poorly controlled diabetes is characterized by increased 
circulating reticulated platelets through induction of an 
FigURe 2 | Mechanistic pathways for increased vascular inflammation in diabetes. Insulin resistance inhibits nitric oxide (NO) synthesis by reducing vasodilation via 
decreased activity of endothelial NO synthase (eNOS) together with increased production of vasoconstrictors such as endothelin-1. Hyperglycemia and increased 
levels of free fatty acids enhance the production of reactive oxygen species (ROS) and reduce NO synthesis via several cellular mechanisms. Free fatty acids bind to 
toll-like receptor which activates the NF-κB pathway and stimulates inflammation by increasing interleukin (IL)-6 and tumor necrosis factor (TNF)-α. Additionally, 
toll-like receptor stimulates the phosphorylation of insulin receptor substrate-1 (IRS-1) followed by downregulation of the PI3-kinase/Akt pathway and the glucose 
transporter GLUT-4, consequently resulting in reduction of NO production.
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inflammatory pathway that leads to increased thrombopoietin 
production. A correlation between HbA1c and reticulated plate-
lets was found in patients with T2DM and improving glycemic 
control, using an agent in the sodium glucose co-transporter-2 
(SGLT2) inhibitor family, reduced reticulated thrombocytosis 
in mice. These findings indicate that one strategy for improved 
efficacy of antiplatelet agents is to reduce circulating reticulated 
platelets, which can be achieved by lowering glucose levels 
using SGLT2 inhibitors. This in turn may help to reduce car-
diovascular risk in patients with diabetes (41). Indeed, studies 
on SGLT2 inhibitors have shown reduction in the composite 
end point of myocardial infarction, stroke, and cardiovascular 
death (42) and controlling platelet reactivity may be one of the 
mechanisms involved.
In addition to enhanced platelet activation, diabetes is asso-
ciated with increased plasma levels and/or activity of various 
coagulation factors. The net result is an enhanced susceptibility 
to forming fibrin networks which are characterized by increased 
density and resistance to fibrinolysis (43, 44). For example, tissue 
factor (TF) and factor VII (FVII) levels are increased in diabetes, 
which in turn explains the enhanced production of thrombin 
leading to higher risk of clot formation. Moreover, plasma levels 
of fibrinogen are increased in diabetes, as part of the ongoing low-
grade inflammation, which contributes to formation of denser 
clots. In addition, anticoagulants, such as thrombomodulin 
and protein C, are reduced in diabetes further predisposing to 
the prothrombotic environment (43, 45). A key antifibrinolytic 
protein is plasminogen activator inhibitor-1 (PAI-1), which 
inhibits conversion of plasminogen to active plasmin. Plasma 
levels of PAI-1 are increased in diabetes, thereby impairing the 
fibrinolytic process. It should be noted that patients with type 2 
diabetes, but not type 1 diabetes, have increased levels of PAI-1 
indicating that IR, rather than hyperglycemia per se, drives the 
increased production of this antifibrinolytic protein, a concept 
that was confirmed using in  vitro and in  vivo studies (9, 44, 
46, 47). Therefore, ameliorating IR would have more of an effect 
on PAI-1 levels than simply improving glycemia in diabetes, 
highlighting some of the complexities involved in the manage-
ment of this condition.
In addition to quantitative changes, qualitative abnormalities 
have been documented in diabetes that increase thrombosis risk. 
This includes altered fibrinogen posttranslational modifications, 
including increased glycation and oxidation, resulting in denser 
fibrin networks (48–51). Also, we have shown that hyperglycemia 
can directly affect the fibrinolytic system by increasing plasmino-
gen glycation, which impairs conversion to plasmin and adversely 
affects protein activity. Interestingly, a relatively modest decrease 
in plasma glucose levels improves plasminogen function, demon-
strating the importance of optimizing glycemic control in these 
patients (52).
FigURe 3 | Mechanistic pathways for increased thrombosis risk in diabetes. The metabolic changes in diabetes are associated with increased platelet activation, 
secondary to reduced nitric oxide (NO) production, an increase in reticulated platelets and increased platelet turnover, which can be only partially controlled by 
antiplatelet therapy. Diabetes is also associated with increased plasma levels of procoagulants and the antifibrinolytic protein levels, including fibrinogen, tissue factor 
(TF), factor VII (FVII), and plasminogen activator inhibitor-1 (PAI-1) as well as decreased levels of anticoagulants, including thrombomodulin and protein C. Moreover, 
qualitative changes in coagulation proteins, including increased oxidation and glycation of fibrinogen, have also been reported in diabetes, which result in the 
formation of thick fibrin networks that are resistant to lysis. Increased glycation of plasminogen compromises conversion to plasmin and alters protein activity. Finally, 
increased incorporation of antifibrinolytic proteins, such as α 2-antiplasmin and complement C3, into the clot impairs fibrinolysis and may represent a new 
therapeutic approach to reduce thrombosis risk in diabetes.
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An interesting, and potentially clinically relevant, mechanism 
for impaired fibrin clot lysis in diabetes is focused on increased 
incorporation of antifibrinolytic proteins into the clot. Alpha 
2-antiplasmin is cross-linked into the fibrin clot and it inhibits 
plasmin by forming a stable complex with this protein. It has been 
reported that type 1 diabetes patients have increased alpha 2-anti-
plasmin incorporation into their fibrin clots (47, 53). Similarly, 
we have shown that complement C3 incorporation into diabetes 
clots is increased in diabetes and directly prolongs clot lysis (54, 
55). Moreover, C3 plasma levels were independent predictors of 
clot lysis in a large cohort of type 2 diabetes patients (56, 57). 
Taken together, modulating incorporation of antifibrinolytic pro-
teins into diabetes clots may represent a new therapeutic strategy 
to reduce thrombotic risk in diabetes. The main mechanisms 
operating to increase thrombosis risk and may represent future 
therapeutic targets in diabetes are summarized in Figure 3.
From Bench to Bedside
Given the pathophysiological mechanisms involved in vascu-
lar pathology in diabetes, there are two main areas to target: 
slowing the progression of atherosclerosis and reducing the 
prothrombotic/hypofibrinolytic environment. Therefore, cur-
rent therapies are directed at improving endothelial function, 
reducing systemic inflammation, and controlling the enhanced 
thrombotic environment.
Targeting Atherosclerosis
In general, improving glycemia and reducing IR, which is part of 
the clinical management strategy in diabetes, have key roles in 
halting the accelerated atherosclerotic process in this condition.
A number of existing agents, and others in development, 
target the inflammatory pathway to reduce atherosclerosis risk. 
Statins, known for their ability to decrease cholesterol levels, have 
also been shown to affect the inflammatory response and this 
dual mode of action explains the efficacy of this class of drugs in 
reducing vascular events in diabetes (58–60).
The initial enthusiasm with preclinical studies involving the 
inhibitor of phospholipase A2 (PLA2) darapladip quickly faded 
with the failure of this agent to reduce coronary vascular events. 
The clinical findings suggest that this enzyme is a biomarker of 
vascular pathology rather than a factor having a direct role in 
pathogenesis. Inadequate dosing and off-target effect(s) have also 
been blamed for failing to demonstrate a clinical benefit with 
this agent so far (61). More studies are currently ongoing that 
will fully clarify the role of PLA2 as an agent that modifies the 
atherosclerotic process (62, 63).
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Experimental studies and preclinical models have indicated 
that IL-1β blockade is effective at preventing coronary artery 
disease. A recent study involving 10,061 patients with previous 
myocardial infarction and C-reactive protein levels above 2 mg/l, 
showed that IL-1 inhibition, using Canakinumab, reduced the 
composite end point of non-fatal myocardial infarction, non-fatal 
stroke, and cardiovascular death by 15 and 14% using 150 and 
300 mg of this agent, respectively (injected once every 3 months). 
However, there was no difference in all-cause mortality, which 
may be related to increased fatal infection in the Canakinumab 
arm of the study.
Antioxidants have been repeatedly considered as potential 
drugs for the prevention and therapy of atherosclerosis given the 
role of ROS in the pathogenesis of atherosclerosis (64). However, 
clinical studies with antioxidants have been generally disap-
pointing; a well-conducted double-blind, randomized, placebo-
controlled study involving 6,144 patients with established CVD 
has shown that the antioxidant succinobucol (AGI-1067) has no 
beneficial effect on vascular outcome, dampening the enthusiasm 
toward such therapy (65). The generally negative results with 
various antioxidant therapies suggest that targeting a single 
pathway involved in vascular pathology is perhaps not enough 
for translation into clinical benefit. The establishment of the 
European consortium for the study of ROS should further help 
to shed more light on the role of this pathway as a therapeutic 
target in vascular pathology, including high-risk conditions such 
as diabetes (66).
Given the pivotal role of endothelial dysfunction in vascular 
pathology, a number of agents that improve EC function are 
currently in clinical use and others are under development. 
Angiotensin-converting (ACE) inhibitors, angiotensin II-receptor 
blockers (ARB), some β blockers, and calcium channel blockers, 
all modulate EC function. However, not all have the same clinical 
effects; for example, ACEI convincingly provide protection from 
future vascular events, whereas the case for ARB is less clear 
despite targeting a largely similar pathway.
Compounds that act directly on guanylate cyclase (sGC), a key 
enzyme of the NO signaling pathway, have also been investigated 
in preclinical studies. The therapeutic potential of sGC activa-
tors (cinaciguat or ataciguat) and sGC stimulators (riociguat) 
has been explored in animal models and clinical trials (67). In 
a recent animal study, it was demonstrated that a sGC activator 
offered renal protection against the progression of nephropathy 
induced by type 2 diabetes in obese rats (68). However, it remains 
unclear whether sGC activators can modulate the risk of vascular 
occlusion in man, and this remains an area for further research.
While all these agents can improve endothelial dysfunction by 
lowering blood pressure, it is clear that additional mechanisms 
operate to explain the difference in vascular outcome (69, 70). It 
has been reported that the thiazolinedione family of hypoglycemic 
agents, improve endothelial dysfunction in patients with type 2 
diabetes by modulating IR (71, 72). Although pioglitazone treat-
ment showed protection from cardiovascular events in diabetes 
(73), treatment with rosiglitazone therapy was associated with an 
increase in vascular events (74). This shows that two agents within 
the same class can have a different clinical outcome, highlighting 
the difficulties in treating vascular disease in diabetes.
Experimental agents to improve EC function include eNOS-
transcription enhancer and agents that inhibit phosphodiester-
ase-5 (PDE-5) and sphingosine-1-phosphate (75, 76). It has been 
shown that the eNOS-transcription enhancer AVE3085 restored 
endothelial function in a hypertensive rat model suggesting that 
drugs regulating eNOS may be considered as therapeutic targets 
(77). Furthermore, PDE-5 inhibitors upregulate eNOS expression 
and, therefore, NO production. It has been reported that these 
inhibitors can improve endothelial function and control platelet 
activation in patients with coronary artery disease and have 
also been shown to improve vascular relaxation in diabetic rats 
(75, 78). Another target that gained an interest is sphingosine-
1-phosphate, which affects the function of cells involved in the 
atherosclerotic process, including monocyte attachment and 
proliferation of smooth muscle cells (79).
Aging and diabetes both cause vascular dysfunction and the 
existence of both conditions has an additive effect in vascular 
damage, leading to increased vascular inflammation and cardio-
vascular risk (80). So far, however, there has been little research 
on the mechanisms of vascular inflammation due to both aging 
and diabetes, which would be particularly helpful to address 
vascular disease in older patients with diabetes.
It has recently been demonstrated that following a coronary 
ischemic event, a single dose of reconstituted HDL increased 
cardiac glucose uptake and reduced infarct size in both metaboli-
cally normal and insulin-resistant mice (81). While these data are 
interesting, further studies are needed to clarify the role of this 
approach in modulating vascular risk in man.
Finally, several studies have investigated the role of miRNAs 
in endothelial dysfunction in diabetes. It has been suggested that 
these noncoding, single-stranded RNA molecules which are 
implicated in key processes such as IR and β-cell function, may 
contribute to the development of prognostic tools or therapeutic 
targets of CVD in diabetes (82). For example, miR-155 has been 
implicated with atherosclerosis via modulation of actin cytoskel-
eton organization in ECs, and it was reported that inhibition of 
miR-155 can reduce atherosclerotic plaques (83). Platelet miR-223 
was reduced in patients with diabetes and in mice which had an 
effect on platelet function. Platelets from miR-223 knockout mice 
had increased aggregation and potential for thrombus formation 
compared to platelets from wild-type mice (84, 85).
The various inflammatory pathways that may represent thera-
peutic targets to reduce vascular risk in diabetes are summarized 
in Figure 4.
Targeting Thrombosis
The thrombotic potential can be modulated both indirectly and 
directly. The former includes measures to reduce IR, optimize 
glycemia, and improve endothelial dysfunction. The latter 
concentrates on antiplatelet therapy as well as agents that target 
coagulation proteins.
Indirect Measures to Improve the Thrombotic 
Environment
Diabetes-specific measures to improve the thrombotic environ-
ment concentrate on ameliorating IR and improving glycemia. 
FigURe 4 | Inflammatory pathways that are currently used or may represent therapeutic targets to reduce vascular risk in diabetes. Current therapies and others in 
development focus on improving the endothelial cell function and reducing vascular inflammation. Established therapies to target endothelial dysfunction are 
angiotensin converting (ACE) inhibitors, angiotensin II-receptor blockers (ARBs), beta blockers, calcium channel blockers, and glitazones, whereas agents such as 
phosphodiesterase-5 inhibitors, endothelial nitric oxide synthase (eNOS) transcription enhancer, and microRNAs represent potential future therapies. Statins are 
widely used to reduce vascular risk and in addition to their cholesterol lowering effect they reduce vascular inflammation. Other potential targets to reduce vascular 
inflammation include of phospholipase A2 (PLA2) inhibitors as well as interleukin (IL)-1 antagonists and antioxidants.
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This can be achieved by simple measures, such as increased 
exercise/adhering to a healthy diet through to sophisticated treat-
ment regimen of intensive glycemic control. Improving glycemia 
reduces platelet activation, modulates fibrin clot structure, and 
improves efficiency of the fibrinolytic system thus ameliorating 
the prothrombotic environment in diabetes. However, the short-
medium term clinical effects of improving glycemia on vascular 
events are debatable with studies showing a benefit, no effect and 
even harm (86–88). The inconsistent results of glycemic studies 
may be related to precipitation of hypoglycemia with tight glyce-
mic control, which can be prothrombotic. We have shown that 
an episode of hypoglycemia creates a prothrombotic and hypofi-
brinolytic environment for at least 1  week (89), explaining the 
association between hypoglycemia, cardiovascular events, and 
mortality (90, 91). Therefore, hypoglycemic agents with lower 
risk of hypoglycemia should be considered in higher vascular risk 
patients with diabetes. In support of this concept, three relatively 
recent trials with hypoglycemic agents that are associated with 
low risk of hypoglycemia have shown improved vascular outcome 
(92–94). It should be acknowledged, however, that the beneficial 
effects of these newer hypoglycemia agents are not solely related 
to avoidance of hypoglycemia and the favorable clinical outcome 
is likely to be due to modulation of a number of cardiovascular 
risk factors.
In addition to glycemia, there has been an interest in the 
antithrombotic properties of omega-3 polyunsaturated fatty acids 
(n-3 PUFAs). However, a recent study demonstrated that treat-
ment with n-3 PUFAs failed to modulate fibrin clot properties, 
platelet activation, or inflammation in patients with atheroscle-
rosis and type 2 diabetes (95).
Direct Measures to Improve the Thrombotic 
Environment
Antiplatelet agents remain a cornerstone in the management of 
the thrombotic environment in diabetes. However, the best treat-
ment regimen at various stages of the vascular pathology is yet 
to be determined; this can be divided into primary prevention, 
secondary prevention immediately following an event and long-
term secondary prevention. This topic is reviewed extensively 
elsewhere (26, 60, 96, 97) and we will only provide here a clini-
cally orientated practical summary.
ANTiPLATeLeT AgeNTS
Primary Prevention
Aspirin irreversibly inhibits cyclo-oxygenase (COX) enzymes, 
at lower doses exhibiting relative selectivity for COX1, which 
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is responsible for the synthesis of thromboxane A2 (TXA2), a 
prothrombotic and vasoconstrictive eicosanoid. At higher doses, 
aspirin can also inhibit COX2, leading to the unwanted reduc-
tion in production of prostacyclin (PGI2) an antithrombotic and 
vasodilatory agent (98). In addition to platelet inhibition, aspirin 
appears to affect the fibrin network structure and fibrinolysis, 
which may also contribute to its clinical antithrombotic effects 
(99).
Until relatively recently, aspirin was used for primary preven-
tion in patients with diabetes, although there was no clear evidence 
supporting such an approach. A number of studies investigating 
aspirin in primary vascular protection in diabetes failed to show 
a benefit, including PPP trial, JPAD, and POPADAD studies, 
and therefore, current guidelines do not advocate the use of this 
agent for primary prevention (100–103). It should be acknowl-
edged that none of these studies was adequately powered to give 
a definitive answer and results from an ongoing large study are 
currently awaited that will clarify the use of aspirin for primary 
prevention in diabetes (ASCEND2). The guidelines adopted a 
pragmatic approach, however, by recommending aspirin use for 
primary prevention in those at higher risk without clearly defin-
ing this group.
One of the issues that remain unresolved is the optimal dos-
ing regimen of aspirin in diabetes. Given the increased platelet 
turnover in diabetes and the relatively short half-life of aspirin, 
this agent may fail to provide 24 h coverage (97, 104). Therefore, 
studies have investigated twice daily administration of aspirin, 
which appears to improve the platelet inhibitory effect, although 
the clinical value of this approach remains unclear (34–36). This 
has been alluded to in joint ESC/EASD guidelines but no manage-
ment recommendations were made due to lack of evidence (103).
Secondary Cardiovascular Prevention
Aspirin is used in combination with other antiplatelet agents that 
target the P2Y12 pathway, following acute coronary syndrome 
(ACS) in diabetes patients and individuals with no diabetes. Of 
the three agents that target the P2Y12 pathway, both prasugrel 
and ticagrelor showed superiority to clopidogrel in improving 
vascular outcome in patients with diabetes (31, 105, 106). A plau-
sible explanation is related to the need to metabolize clopidogrel 
from the inactive to the active form, which is simpler process with 
prasugrel and not required at all with ticagrelor.
Dual antiplatelet therapy is usually continued for a period of 
1 year after an ACS to be followed by aspirin only therapy that is 
continued indefinitely. However, recent evidence indicates that 
longer-term DAPT therapy with aspirin and ticagrelor offers a 
survival advantage in diabetes patients, unlike those without 
diabetes (107). The safety and cost effectiveness of this approach 
requires further analysis and/or studies before routinely recom-
mending long-term DAPT in patients with diabetes (26, 31, 
105, 106).
An inherent difficulty in optimizing antiplatelet therapy in 
diabetes is related to the heterogeneity of this condition and the 
2 https://clinicaltrials.gov/ct2/show/NCT00135226.
variable vascular risk according to duration of diabetes, treat-
ment modalities, and presence of microvascular complications. 
In order to optimize antiplatelet therapy in diabetes, there are a 
number of questions that remain unanswered, including: (i) Is 
an alternative dosing of aspirin required in diabetes? (ii) How 
long to continue treatment with DAT following ACS? (iii) Are 
different antiplatelet regimen required in different groups of 
diabetes patients, particularly for primary prevention? (iv) Are 
additional antiplatelet agents that target other pathways required? 
Addressing these questions will require large clinical outcome 
studies which are both time consuming and expensive. Therefore, 
using surrogate markers, such as platelet activation tests, may 
provide provisional data justifying clinical outcome studies. In 
other words, an integrated bench to bedside approach is perhaps 
the most cost effective way to investigate newer antithrombotic 
agents or analyze alternative application of existing agents.
AgeNTS TARgeTiNg THe COAgULATiON 
PATHwAY
established Therapies
Proteins of the contact system have been investigated and con-
sidered as therapeutic targets due to their important role in the 
initiation of thrombosis. TF is expressed by exposed vascular 
smooth muscle cells at the atherosclerotic plaque rupture sites 
where it triggers the activation of FVII and the initiation of the 
coagulation cascade. Activation of FIX and FX by the TF/FVIIa 
complex then leads to the formation of FXa/FVa complex which 
converts prothrombin into thrombin (108).
Heparin is an indirect inhibitor of FX and prothrombin and is 
used in diabetes and non-diabetes subjects with ACS. It is mainly 
used in unfractionated form or as the low-molecular weight form 
of heparin, named enoxaparin, which has been suggested to be 
more effective than the unfractionated form of heparin (109). 
Another indirect inhibitor of FX which was reported to be as 
effective as enoxaparin or unfractionated heparin is fondaparinux 
(110). However, unlike heparin, fondaparinux fails to inhibit 
thrombin.
The recent development of direct oral anticoagulants has fur-
ther helped by offering a more targeted inhibition of the protein 
arm of coagulation. Bivalirudin is a direct inhibitor of thrombin 
which has been reported to be superior to heparin as a therapy 
for diabetes patients with ACS due to the significant reduction in 
bleeding complications in some studies (111, 112). The COMPASS 
study, involving over 27,000 patients with stable coronary artery 
disease, has recently shown that combination of rivaroxaban (FX 
inhibitor) with aspirin is superior to aspirin alone in preventing 
vascular events, an observation that applied to both patients with 
and without diabetes (113). However, there was a 70% increase 
in bleeding risk in patients receiving combination therapy, which 
is a concern and will have implications for the widespread use of 
such a therapy.
experimental Therapies
FXII and FXI are involved upstream in the coagulation system 
and have been considered as potential therapeutic targets for 
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thrombosis prevention. Activation of FXII triggers the initiation 
of the contact system and FXIIa converts prekallikrein to kal-
likrein. Kallikrein promotes the generation of additional FXIIa 
and the activation of FXI. Finally, FXIa activates FIX and promotes 
FX activation and generation of thrombin. The antithrombotic 
effects of targeting FXII and prekallikrein have been demon-
strated in vivo using FeCl3- induced and stenosis-induced models 
of venous thrombosis (114). Different approaches, such as the use 
of antibodies, small molecules and aptamers have been developed 
to target factor XII and FXI but the clinical efficacy and safety of 
such drugs in man are yet to be determined (115).
A crucial element of a successful antithrombotic therapy is 
maintaining a clinically acceptable risk/benefit ratio. This requires 
close understanding of the mechanistic pathways operating to 
increase thrombosis risk in diabetes. For example, it has been 
shown that both PI and complement C3 incorporation into dia-
betes clots is enhanced, which further compromises fibrinolysis 
(detailed above). Developing therapies that reduce incorporation 
of these proteins into diabetes clots will facilitate fibrinolysis, 
thus limiting thrombus formation while keeping bleeding risk to 
a minimum. Therefore, rather than full inhibition of one pathway, 
which compromises normal physiology and increases bleeding 
risk, what is perhaps required is partial inhibition of multiple 
pathways with a focus on those that show a diabetes-specific 
abnormality.
Potential treatments and targets to further reduce athero-
thrombosis risk in diabetes are summarized in Figure 5.
CONCLUSiON AND THe wAY FORwARD
Research conducted for the prevention and treatment of athero-
thrombotic disease has seen major advances over the past few 
decades, which translated clinically into significant improvement 
in vascular mortality and morbidity. We now have a number of 
agents that limit the atherosclerotic process and also control the 
risk of thrombosis. Despite these advances, however, the risk of 
vascular disease in patients with diabetes remains unacceptably 
high with relatively poor prognosis following an ischemic event. 
Therefore, future work is required to develop more effective 
therapeutic agents to halt the accelerated atherosclerotic process, 
typically associated with diabetes. Moreover, work is needed to 
develop antithrombotic strategies that target diabetes-specific 
pathways, thereby maximizing benefit and limiting the risk of 
bleeding. These include alternative use of existing agents and 
development of novel agents. An example of the former is inves-
tigating the efficacy of twice daily aspirin regimen in diabetes, 
FigURe 5 | Thrombotic pathways that represent current and potential therapeutic targets in diabetes. Indirect measures to improve the thrombotic environment in 
diabetes focus on optimizing glycemic control by lowering glucose levels while avoiding hypoglycemia and also by reducing insulin resistance. Antiplatelets and 
agents that target the coagulation system comprise the main direct measures to manage the thrombotic environment in diabetes. Aspirin targets the thromboxane 
pathway and is also used in combination with clopidogrel, prasugrel, or ticagrelor which target the P2Y12 pathway. Alternative antiplatelet targets are under 
consideration. Vitamin K antagonism reduces thrombosis risk but is associated with high risk of bleeding when combined with antiplatelet therapy, and therefore, not 
routinely used for atherothrombotic disease. Inhibitors of coagulation proteins FX and thrombin, such as heparin and direct oral anticoagulants, represent agents 
with promise in diabetes while targeting factor (F)XII and FXI requires careful future evaluation. Alternative dosing of aspirin and reduction of incorporation of 
antifibrinolytic proteins into the clot may represent new approaches to improve clinical outcome in patients with diabetes.
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